Years of non-small cell lung cancer (NSCLC) research are beginning to result in significant gains in the standard of care, specifically for patients eligible for anti-PD-1 therapy. As all anti-PD-1s have the same pricing, the benefit of multiple approvals has not resulted in typical market behavior. The future challenge is to define the immunotherapy landscape and combination rationale, with a personalized, patient-centric approach.

We assess the status of immunotherapies in NSCLC and how marketers should leverage new combination strategies to meet unmet needs of specific patient populations and ensure market access as these new treatments evolve and take hold.

Read the full article here